Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Allergan reports strong growth in Q3 2013

Allergan reports strong growth in Q3 2013

4th November 2013

Allergan has published its financial report for the third quarter of 2013, during which the company achieved strong double-digit year-on-year growth.

The company's total product net sales for the quarter came to $1.53 billion (956 million pounds), up by 12.9 percent compared to Q3 2012, with both its pharmaceutical and medical device divisions performing well.

During the three-month period, the firm was able to achieve key US regulatory approvals for Juvederm Voluma XC and Botox, entered into a new alliance with Medytox and also recently confirmed the sale of its obesity intervention business to Apollo Endosurgery.

For 2013 as a whole, Allergan's total sales are expected to fall between the range of $6.13 billion and $6.2 billion.

David Pyott, Allergan's chairman of the board and chief executive officer, said: "We are pleased with our continued broad-based double-digit sales and earnings growth performance during the third quarter, driven by both our pharmaceutical and medical device businesses."

Established in 1950, the company is a multinational healthcare company with expertise in the fields of eye care, neuroscience, medical dermatology, medical aesthetics, obesity intervention and urologics.ADNFCR-8000103-ID-801656578-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.